Skip to content

Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair & Same-Session Implantation

Management of Urethral Injury During Penile Prosthesis Implantation: Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair and Same-Session Implantation

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03614429
Enrollment
100
Registered
2018-08-03
Start date
2018-06-01
Completion date
2018-12-01
Last updated
2018-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Penile Prosthesis; Complications

Keywords

Penile Prosthesis, Urethral injury, Urethral sterilization

Brief summary

The introduction of penile implants has revolutionized the management of male erectile dysfunction. However, a number of intraoperative complications may occur, which have a major impact on clinical outcomes and patient satisfaction such as bleeding, infection and urethral injury. Patients undergoing penile implant surgery with fibrotic corpora (e.g., after priapism, after infection, or with Peyronie disease) have a higher risk rates of urethral perforation. This may be related to previous scarring, the difficultly in dilating scarred and fibrotic corpora and its inherent risk of corporal crossover and urethral perforation. This work examines the efficacy of pre-operative urethral sterilization in rendering the urethra as sterile as the skin of the genital area, with the skin sterilized as per the ISSM guidelines for penile prosthesis implantation, thereby allowing primary repair of urethral injuries should they occur, and implantation in the same setting, without a higher risk of infection. The study will involve 100 male patients undergoing aseptic surgery (regardless the procedure). Patients will be divided into two groups: Group 1: control group, n=50 Group 2: Chlorhexidine group (Ch group), n=50 Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed. After conclusion of surgery and with the patient on the operative table, the following swabs will be obtained: * A penile skin swab. * A urethral swab. Skin and urethral swabs will be compared for bacterial colonization by culture and sensitivity, across the two groups.

Detailed description

study design Comparative experimental (interventional) study Sample size The study will involve 100 male patients undergoing aseptic surgery (regardless the procedure). Patients will be divided into two groups: Group 1: control group, n=50 Group 2: Chlorhexidine group (Ch group), n=50 Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed. Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition: 6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216) The other ingredients are: Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not. For both groups, skin sterilization will be performed according to the ISSM International Society of Sexual Medicine guidelines for skin preparation before penile prosthesis surgery (Darren J. Katz et.al 2012) After conclusion of surgery and with the patient on the operative table, the following swabs will be obtained: * A penile skin swab. * A urethral swab.

Interventions

DRUGChlorhexidine gel will be prepared according to an international product Instillagel®

Pre-operatively, urethral instillation with Chlorhexidine gel will be performed for the Ch group, while for the control group, instillation will not be performed. Chlorhexidine gel will be prepared according to an international product; Instillagel®, used prior to urethral catheterization as analgesic / anti-septic, with the following composition: 6ml of Instillagel® gel contain: 117.6mg lidocaine hydrochloride, 3.1mg chlorhexidine digluconate, 3.8mg methyl hydroxybenzoate (E218), 1.6mg propyl hydroxybenzoate (E216) 11ml of Instillagel® gel contain: 215.7mg lidocaine hydrochloride, 5.8mg chlorhexidine digluconate, 6.9mg methyl hydroxybenzoate (E218), 2.9mg propyl hydroxybenzoate (E216) The other ingredients are: Hyetellose, propylene glycol\* (E 1520), sodium hydroxide and purified water. Intra-operatively, the Ch group will receive Chlorhexidine instillation again before surgery, while the control group will not.

Sponsors

Cairo University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Intervention model description

Comparative experimental (interventional) controlled study

Eligibility

Sex/Gender
MALE
Age
21 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Male patients aged 20-50 years-old or older undergoing a sterile surgical procedure

Exclusion criteria

* Unwilling patient for this procedure * Patients with history of urethral surgery, urinary calculi, urethral structure, or ongoing pyospermia, prostatitis or pyuria will be excluded, and so will be patients undergoing non-sterile surgeries such as abscess drainage.

Design outcomes

Primary

MeasureTime frameDescription
Bacterial colonization by culture and sensitivity4 daysAfter conclusion of surgery and with the patient on the operative table, the following swabs will be obtained: * A penile skin swab. * A urethral swab. Skin and urethral swabs will be compared for bacterial colonization by culture and sensitivity, across the two groups.

Countries

Egypt

Contacts

Primary ContactOsama K Shaeer, M.D., PhD
osamashaeer@gmail.com+201006600606
Backup ContactIslam F.S. Abdelrahman, M.D.
islamandrology@yahoo.com+201004244360

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026